In the last trading session, 1.65 million Bluebird bio Inc (NASDAQ:BLUE) shares changed hands as the company’s beta touched 0.76. With the company’s per share price at $4.05 changed hands at -$0.03 or -0.74% during last session, the market valuation stood at $39.38M. BLUE’s last price was a discount, traded about -848.15% off its 52-week high of $38.40. The share price had its 52-week low at $4.00, which suggests the last value was 1.23% up since then.
Analysts gave the Bluebird bio Inc (BLUE) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.83. If we narrow down to specifics, the data shows that 1 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended BLUE as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Bluebird bio Inc’s EPS for the current quarter is expected to be -6.3.
Bluebird bio Inc (NASDAQ:BLUE) trade information
Instantly BLUE was in red as seen at the end of in last trading. With action -44.29%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -51.44%, with the 5-day performance at -44.29% in the red. However, in the 30-day time frame, Bluebird bio Inc (NASDAQ:BLUE) is -48.54% down.
The consensus price target for the stock as assigned by Wall Street analysts is 12.5, meaning bulls need an upside of 67.6% from its current market value. According to analyst projections, BLUE’s forecast low is 5 with 25 as the target high. To hit the forecast high, the stock’s price needs a -517.28% plunge from its current level, while the stock would need to soar -23.46% for it to hit the projected low.
Bluebird bio Inc (BLUE) estimates and forecasts
Year-over-year growth is forecast to reach 148.32% up from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 27.07M. 5 analysts are of the opinion that Bluebird bio Inc’s revenue for the current quarter will be 37.91M. The company’s revenue for the corresponding quarters a year ago was 7.83M and 18.57M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 245.57%. The estimates for the next quarter sales put growth at 104.10%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 28.98%. The 2025 estimates are for Bluebird bio Inc earnings to increase by 31.92%.
BLUE Dividends
Bluebird bio Inc is expected to release its next quarterly earnings report in March.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 9.4422% or 10.3 million shares worth $10.14 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . With 293.12 shares estimated at $1.19 million under it, the former controlled 0.15% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 0.14% of the shares, roughly 271.46 shares worth around $1.1 million.
